Based on the phase III Keynote-811 trial (Janjigian et al. 2021b), the FDA has approved pembrolizumab and trastuzumab plus chemotherapy as first-line therapy for patients with HER2-positive irremovable advanced GC/GEJA. The gene discussed is ERBB2; the disease is gastric cancer.